[go: up one dir, main page]

CN111701019B - Application of Dmatg5 gene in preparation of anti-salmonella enteritidis medicine - Google Patents

Application of Dmatg5 gene in preparation of anti-salmonella enteritidis medicine Download PDF

Info

Publication number
CN111701019B
CN111701019B CN202010473672.XA CN202010473672A CN111701019B CN 111701019 B CN111701019 B CN 111701019B CN 202010473672 A CN202010473672 A CN 202010473672A CN 111701019 B CN111701019 B CN 111701019B
Authority
CN
China
Prior art keywords
gene
salmonella enteritidis
dmatg5
drosophila
sirna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202010473672.XA
Other languages
Chinese (zh)
Other versions
CN111701019A (en
Inventor
田铃
李荣松
吴坤钟
吴文梅
黄志君
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
South China Agricultural University
Original Assignee
South China Agricultural University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by South China Agricultural University filed Critical South China Agricultural University
Priority to CN202010473672.XA priority Critical patent/CN111701019B/en
Publication of CN111701019A publication Critical patent/CN111701019A/en
Application granted granted Critical
Publication of CN111701019B publication Critical patent/CN111701019B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明涉及基因工程技术领域，特别涉及DmAtg5基因在制备抗肠炎沙门氏杆菌药物中的用途。本发明人在研究中发现肠炎沙门氏杆菌可以侵染果蝇细胞，并诱导了果蝇DmAtg5基因的表达，在此基础上设计了果蝇DmAtg5基因的siRNA验证了其在抗肠炎沙门氏杆菌中的作用；同时，开发了一种快速检测果蝇细胞中肠炎沙门氏杆菌增殖情况的方法，为深入研究肠炎沙门氏杆菌等胞内寄生菌与宿主之间的互作，进而开发和利用抗肠炎沙门氏杆菌的靶点奠定基础。

Figure 202010473672

The invention relates to the technical field of genetic engineering, in particular to the use of DmAtg5 gene in the preparation of anti-Salmonella enteritidis medicines. The inventors found in research that Salmonella Enteritidis can infect Drosophila cells and induce the expression of DmAtg5 gene in Drosophila. At the same time, a rapid detection method of Salmonella Enteritidis proliferation in Drosophila cells was developed, in order to further study the interaction between Salmonella Enteritidis and other intracellular parasites and the host, and then develop and utilize anti-enteritis Salmonella targets lay the groundwork.

Figure 202010473672

Description

Application of Dmatg5 gene in preparation of anti-salmonella enteritidis medicine
Technical Field
The invention relates to the technical field of genetic engineering, in particular to application of a Dmatg5 gene in preparation of a salmonella enteritidis resistant drug.
Background
Autophagy (autophag) is an evolutionarily highly conserved process widely existing in eukaryotes, used for degrading and recycling biomacromolecules and damaged organelles in cells, is an important mechanism for maintaining metabolism and self-stabilization of organisms, and is closely related to various physiological and pathological processes of the organisms. Autophagy occurs throughout under the control of different autophagy-related proteins (ATG or ATG). Autophagy is an evolutionarily conserved process of cellular metabolism and breakdown, and at the same time plays an important role as an immune response during pathogen infection. Autophagy is the major type of autophagy and is characterized by the formation of bilayer membrane autophagosomes, which require the involvement of a series of autophagy-related proteins, two important ubiquitin-like protein systems, ATG5-ATG12, ATG16 and LC3/ATG 8-PE. Studies by Radhi et al (Radhi, o.a., Davidson, s., Scott, f., Zeng, r.x., Jones, d.h., Tomkinson, n.c.o., Yu, j., and Chan, e.y.w. (2019) Inhibition of the ULK1protein complex applied staphylococcus-induced autophagy and cell death.j Biol chem294,14289-14307) show that the ATG protein has a certain relationship to the virulence of a bacterium or viral pathogen. In mammals, down-regulation of the ULK1-ATG13 protein complex inhibits intracellular proliferation and host cell death of staphylococcus aureus. Bechelli et al (Bechelli, J., Vergara, L., Smalley, C., Buzhdygan, T.P., Bender, S., Zhang, W., Liu, Y., Popov, V.L., Wang, J., and Garg, N., et al (2019) Atg5supports Rickettsia australis infection in mammdevices in vitro and video in vivo in animal 87, Pahari, S., Negi, S., Aqdas, M., netArt, E., Schlesinger, L.S., and Agrewala, J.N (2019) expression of animal tissue EC4 in tissue 56, and Mycobacterium 3, Mycobacterium 3, Mycobacterium; ATG5 activates IL-1 β expression in mouse macrophages through a non-classical autophagy pathway, and plays a positive role in defense against rickettsial infections.
Many bacterial diseases are both human and animal diseases, and have great harm to human health and livestock and animal production. Salmonella enteritidis (Salmonella enteritidis) is an important pathogen of zoonosis, which not only affects the development of animal husbandry, but also brings serious harm to human health. In recent years, with the abuse of antibiotics in production and daily life, studies in some pathogenic bacteria such as Salmonella typhimurium have found that they have developed strong resistance and have a tendency toward the evolution of superbacteria. With the requirements of no antibiotic addition, environmental safety and the like in animal husbandry, how to adopt a new method and means to prevent and treat bacterial pathogens becomes an urgent priority.
Disclosure of Invention
The present invention is directed to solving at least one of the problems of the prior art. Therefore, the invention provides the application of the Atg gene in preparing an anti-salmonella enteritidis drug.
The technical scheme of the invention is shown as follows.
The invention provides an application of ATG5 gene in preparing anti-Salmonella enteritidis medicine.
According to some embodiments of the invention, the ATG5 gene is drosophila DmAtg5 gene.
Although the prior art has studied the correlation between the expression of the ATG gene and the virulence of a bacterial or viral pathogen, the mechanism is not clear; and is also irregularly related to the pathogenicity of any pathogenic bacteria. The drosophila melanogaster, as a common model organism, provides a very favorable reference and leading effect for human related researches in the researches of analyzing embryonic development, innate immunity and the like. The research shows that the pathogens of many mammals can also infect the cells or living bodies of the drosophila, and the established drosophila-pathogen intermediate research model discovers pathogen-host or action and host defense mechanisms which are not found in many original hosts and provides a basis for explaining the infection, pathogenesis and prevention and treatment of related pathogens. Through a large amount of scientific researches, the inventor discovers that after the Dmagg 5 gene of the drosophila is inhibited, the proliferation of the Salmonella enteritidis in the cell is obviously higher than that of a blank control group by carrying out an infection test of the Salmonella enteritidis, namely, the resistance to the Salmonella enteritidis is reduced by inhibiting the expression of the Dmagg 5; therefore, the Dmatg gene, especially the Dmatg5 gene is expected to be a key target for inhibiting the salmonella enteritidis and plays an important role in preparing anti-salmonella enteritidis drugs.
According to some embodiments of the invention, the anti-salmonella enteritidis drug comprises a substance that enhances expression of the DmAtg5 gene, preferably, the substance is a small molecule substance and compound that enhances expression of the DmAtg5 gene.
The inventor researches and discovers that the bacterial infection resistance of cells can be reduced by inhibiting the expression of the Dmatg5 gene, so that the bacterial infection resistance can be increased by highly expressing the Dmatg5 gene.
According to some embodiments of the invention, the primer sequence used for detecting the salmonella enteritidis is
Dmrp49-F：GACAGTATCTGATGCCCAACA；
Dmrp49-R：CTTCTTGGAGGAGACGCCGT；
InvC-F：TCAAGAATAGAGCGAATTTCATCC；
InvC-R：TGCTTTTTATCGATTCCATGACCC。
The traditional method for detecting the salmonella enteritidis can only detect the existence of the salmonella enteritidis, but cannot be used for evaluating the proliferation condition of the salmonella enteritidis in host cells.
The invention also provides application of the ATG5 gene in screening drugs for inhibiting the activity of Salmonella enteritidis. Preferably, the ATG5 gene is Drosophila DmAtg5 gene.
In another aspect, the invention also provides an siRNA for inhibiting the expression of the Dmatg5 gene.
According to some embodiments of the invention, the nucleotide sequence of the siRNA is
F：GCAUUAAGCCGGAGCCUUUTT；
R：AAAGGCUCCGGCUUAAUGCTT。
The inventor designs siRNA for synthesizing DmaAtg 5 gene of drosophila melanogaster and verifies the function of the siRNA in resisting salmonella enteritidis; the siRNA of the Dmatg5 gene is convenient to synthesize, has obvious interference efficiency on a target gene, and can be used as an effective means and method for future related research and application.
According to some embodiments of the invention, the siRNA may be used in screening for a bacteriostatic active drug.
The invention also provides the application of the siRNA in screening bacteriostatic active medicines.
In still another aspect, the invention provides the use of the siRNA as described above in screening drugs for inhibiting the activity of Salmonella enteritidis.
The inventor finds that the salmonella enteritidis can infect drosophila cells and induces the expression of the drosophila DmAtg5 gene, and the expression of the drosophila DmAtg5 gene has a positive and effective effect on resisting the salmonella enteritidis. The DmAtg5 gene of the drosophila melanogaster is the main DmAtg gene induced after infection of salmonella enteritidis, and siRNA of the DmAtg5 gene of the drosophila melanogaster is designed on the basis to verify the effect of the gene in resisting salmonella enteritidis; meanwhile, a method for rapidly detecting the proliferation condition of salmonella enteritidis in drosophila cells is developed, and a foundation is laid for deeply researching the interaction between intracellular parasitic bacteria such as salmonella enteritidis and the like and a host and further developing and utilizing a target point of salmonella enteritidis resistance.
Drawings
FIG. 1 is a graph showing the effect of Salmonella enteritidis infection of Drosophila cells on the Dmatg gene;
FIG. 2 is a diagram showing the interference of siRNA to Dmatg5 gene;
FIG. 3 is a graph showing the inhibitory effect of Drosophila DmaAtg 5 gene on Salmonella enteritidis proliferation.
Detailed Description
The technical solutions and effects of the present invention will be further described and illustrated with reference to the following specific examples, but the present invention is not limited to these specific embodiments. The test methods used in the examples are all conventional methods unless otherwise specified; the materials, reagents and the like used are commercially available reagents and materials unless otherwise specified.
Example 1 Effect of Salmonella enteritidis infection of Drosophila cells on the Dmatg Gene
(1) Salmonella enteritidis infecting Drosophila S2 cells
3 biological replicates were established for each of the control and experimental groups.
Experimental groups were treated as follows: taking a 6-well plate as an example, drosophila S2 cells were plated for 18h in instect SIM SF medium (MSF1-1, sinand biol., china) containing 5% fetal bovine serum (FBS500-S, AusGeneX, australia), incubated with 50nM of water soluble cholesterol (134428, biberery, china) for 30min per well, followed by addition of salmonella enteritidis suspension (approximately 20 bacteria) and incubation at 28 ℃ for 1.5 h. The Drosophila S2 cells were then washed twice with phosphate buffered saline (PBS, pH7.4) in 100. mu.M CuSO4And 10. mu.g/mL gentamicin in Insect SIM SF medium for 3 h. And washed twice with PBS.
Treatment of the control group: the same experiment group was performed without adding Salmonella enteritidis suspension.
(2) Collection of Drosophila s2 cells
The cell samples were transferred to 1.5mL RNase-free centrifuge tubes, centrifuged at 3,000g for 5min, the supernatant discarded, and the cell pellet retained for further experiments.
(3) RNA extraction is carried out on the precipitate, and interference efficiency is detected by utilizing a qPCR technology, and the method comprises the following specific steps:
(I) 1mL of TRIzol reagent was added to the above precipitate, and the mixture was thoroughly mixed and allowed to stand for 5 min.
(II) adding 200 mu L of trichloromethane, fully and uniformly mixing, and standing for 5 min.
(III) centrifuging at 12,000r/min below 4 deg.C for 15min, slowly transferring supernatant, placing in a new RNA-free enzyme centrifuge tube, adding isopropanol with equal volume, slowly mixing, and placing on ice box for about 20 min.
(IV) centrifuging at 12,000r/min below 4 deg.C for 10min, removing supernatant, adding 75% ethanol, and slowly resuspending and washing the precipitate.
(V) centrifuging at 12,000r/min below 4 deg.C for 10min, removing supernatant, blotting residual liquid, and adding appropriate amount of double distilled water without RNase.
(VI) the quality and concentration of RNA was determined by agarose gel electrophoresis and NanoDrop. After cDNA was generated by reverse transcription of RNA samples qualified in the detection using PrimeScriptTM RT kit (RR047A, TaKaRa, Japan), the change of autophagy genes Dmag 1, Dmag 5 and Dmagg 6 of Drosophila S2 cells in mRNA level was detected by qPCR technique.
The detection results are shown in fig. 1, and it can be seen that compared with the control, the expression levels of Dmatg5 and Dmatg6 are remarkably increased, and the expression levels of Dmatg5 are the most remarkably increased, which indicates that the Dmatg5 gene is the main Dmatg gene after the infection induction of the salmonella enteritidis. (experimental data analyzed by t-test, "+" indicates p <0.05, "+" indicates p <0.01, "+" indicates p < 0.001; values are expressed as mean ± sd of three independent biological replicates)
Example 2 interference of siRNA to Dmatg5 Gene
(1) Designing siRNA of DmAtg5 gene of drosophila S2 cells, wherein the sequence is F: GCAUUAAGCCGGAGCCUUUTT; AAAGGCUCCGGCUUAAUGCTT is added.
(2) siRNA of DmaAtg 5 gene was synthesized.
(3) The siRNA carries out RNA interference treatment on Dmagg 5 gene of Drosophila S2 cells.
Experimental groups: performing RNA interference treatment on DmAtg5 gene of Drosophila S2 cells for 48 h;
the specific operation is as follows:
for example, S2 cells were first plated into 6-well plates using Insect SIM SF medium (MSF1-1, Xinhe Biopsis, China) containing 5% fetal bovine serum (FBS500-S, AusGeneX, Australia). When the density is 60% -70%, transfection is carried out.
The transfection procedure was as follows:
step 1, serum-free SIM-SF culture medium and transfection reagent are put to room temperature in advance;
step 2, 200. mu.L of culture medium was taken from each well in a 1.5mL centrifuge tube according to the siRNA and transfection reagent: (
Figure BDA0002515123880000061
HD Transfection Reagent Promega, Madison, WI Cat # E2311) in a mass-to-volume ratio of 1:3, mixing in a centrifuge tube, standing for 10-15 min;
and 3, suspending and dripping the transfection mixed solution into a 6-well plate, changing the solution after 12 hours, and carrying out next treatment after 48 hours.
The control group is added with the siRNA of egfp gene, other operations are the same as those of the experimental group, and the subsequent treatment is also the same.
(4) The cell samples were transferred to 1.5mL RNase-free centrifuge tubes, centrifuged at 3,000g for 5min, the supernatant discarded, and the cell pellet retained for further experiments.
(5) RNA extraction is carried out on the precipitate, and interference efficiency is detected by utilizing a qPCR technology, and the method comprises the following specific steps:
(I) 1mL of TRIzol reagent was added to the above precipitate, and the mixture was thoroughly mixed and allowed to stand for 5 min.
(II) adding 200 mu L of trichloromethane, fully and uniformly mixing, and standing for 5 min.
(III) centrifuging at 12,000r/min below 4 deg.C for 15min, slowly transferring supernatant, placing in a new RNA-free enzyme centrifuge tube, adding isopropanol with equal volume, slowly mixing, and placing on ice box for about 20 min.
(IV) centrifuging at 12,000r/min below 4 deg.C for 10min, removing supernatant, adding 75% ethanol, and slowly resuspending and washing the precipitate.
(V) centrifuging at 12,000r/min below 4 deg.C for 10min, removing supernatant, blotting residual liquid, and adding appropriate amount of double distilled water without RNase.
(VI) the quality and concentration of RNA was determined by agarose gel electrophoresis and NanoDrop. After the RNA sample which is qualified for detection is subjected to reverse transcription by a PrimeScriptTM RT kit (RR047A, TaKaRa, Japan) to generate cDNA, the copy numbers of the Dmatg5 and Dmrp49 genes are detected by a qPCR technology, and the RNA interference efficiency of an experimental group relative to a control group can be visually seen after calculation. The interference efficiency was calculated to be 69.1%.
As shown in fig. 2, the results of siRNA interference with DmAtg5 gene are shown in the graph, where the ordinate represents the change in expression level of DmAtg5 gene after siRNA treatment of egfp gene and DmAtg5 gene in drosophila S2 cells, the abscissa represents different treatment groups, NC represents a control group (siRNA treatment of egfp gene on drosophila S2 cells), and DmAtg5RNAi represents an experimental group (siRNA treatment of DmAtg5 gene on drosophila S2 cells). As shown in the figure, after RNA interference is carried out on DmAtg5 gene of Drosophila by the siRNA, compared with a control group, the expression level of the DmAtg5 gene in an experimental group is obviously reduced, and the interference efficiency is obvious. (experimental data analyzed by t-test, "+" indicates p <0.05, "+" indicates p <0.01, "+" indicates p < 0.001; values are expressed as mean ± sd of three independent biological replicates)
Example 3 inhibitory Effect of Drosophila DmaAtg 5 Gene on Salmonella enteritidis proliferation
(1) RNA interference of Drosophila DmaAtg 5 gene
The experimental group and the control group are respectively provided with 3 biological replicates, and the operation of the experimental group is as follows: the RNA interference treatment of DmAtg5 gene of Drosophila S2 cells was performed for 48h by using siRNA of DmAtg5 in the present invention, and the specific procedure was the same as that of example 2.
Egfp siRNA was added to the control group, and the other operations were the same as those of the experimental group, and the subsequent treatments were the same.
(2) Salmonella enteritidis treatment
Adding 50nM water-soluble cholesterol into each well of the 6-well plate, and incubating for 30 min; adding the bacterial suspension in an amount of 20 bacteria/cell; culturing at 28 ℃ for 1.5h, and then washing the cells twice with PBS; liquid changing; adding a solution containing 100 μ M CuSO4And SIM-SF culture medium of 10 mu g/mL gentamicin for 3 h; washing twice with PBS; the cell samples were transferred to 1.5mL centrifuge tubes, centrifuged at 3,000g for 5min, the supernatant discarded, and the pellet retained for further experiments.
(3) Detecting the proliferation condition of salmonella enteritidis: extracting the genome DNA of the precipitate by using a genome extraction kit (D3129-01, magenta, China), and detecting the proliferation condition of the salmonella enteritidis by using a qPCR technology, wherein the specific operations are as follows:
(I) 20 mu.L of protease K, 230 mu.L of buffer ITL and 180 mu.L of lysozyme (prepared into 20mg/mL by using buffer TE) are added into the precipitate, and the mixture is bathed for 2 hours at 37 ℃ to achieve the effects of digesting cells and cracking parasitic bacteria.
(II) Add 500. mu.L of buffer IL (diluted with absolute ethanol) to the digest and vortex for 30 s.
(III) HiPureg DNA micro column was loaded into a 2mL collection tube. The resulting mixture (including the precipitate) was transferred to a column. Centrifugation is carried out for 1min at 10000 g.
(IV) the filtrate is discarded and the column is returned to the collection tube. 600 μ L of buffer GW1 (diluted with absolute ethanol) was added to the column. 10000g for 1min, repeat this step 2 times.
(V) the filtrate was decanted and 75% by volume ethanol was added to 10000g of the column and centrifuged for 1 min.
(VI) the filtrate is decanted and the column is returned to the collection tube. 13000g for 3 min.
(VII) pouring off the filtrate, and standing for 3-5 min.
(VIII) the column was placed in a fresh 1.5mL centrifuge tube. Adding 30-50 μ L buffer AE preheated to 65 deg.C to the center of the column membrane, standing for 3min, centrifuging at 10000g for 1min, and collecting DNA
(IX) copy numbers of Drosophila Dmrp49 gene and Salmonella enteritidis InvC gene in the above DNA were determined by qPCR technique.
The sequence of a quantitative primer of the Dmrp49 gene is F: GACAGTATCTGATGCCCAACA, respectively; r: CTTCTTGGAGGAGACGCCGT, respectively;
the quantitative primer sequence of the InvC gene is F: TCAAGAATAGAGCGAATTTCATCC, respectively; r: TGCTTTTTATCGATTCCATGACCC are provided.
(4) Data processing
The expression quantities of the InvC gene and the Dmrp49 gene in the experimental group and the control group are respectively calculated, the ratio of the expression quantities is taken as a vertical coordinate, different processing groups are used as a horizontal coordinate to map, and the relationship between the proliferation condition of the salmonella enteritidis and the copy number of the Dmatg5 gene can be visually seen.
The results are shown in FIG. 3, the ordinate indicates the change in copy number of Salmonella enteritidis InvC gene after siRNA treatment of egfp gene and Dmatg5 gene, the abscissa indicates different treatment groups, NC is control group (SiRNA treatment of egfp gene on Drosophila S2 cells), and Dmatg5RNAi is experimental group (SiRNA treatment of Dmatg5 gene on Drosophila S2 cells). The figure shows that the proliferation of the salmonella enteritidis after the siRNA treatment of the Dmatg5 gene is obviously higher than that of a control group, namely, the drosophila S2 cells are more easily infected by the salmonella enteritidis after the RNA interference is carried out on the Dmatg5 gene. (experimental data analyzed by t-test, "+" indicates p <0.05, "+" indicates p <0.01, "+" indicates p < 0.001; values are expressed as mean ± sd of three independent biological replicates)
While the invention has been disclosed with reference to specific embodiments, it will be apparent that other embodiments and variations of the invention may be devised by those skilled in the art without departing from the true spirit and scope of the invention, and it is intended that the following claims be interpreted to include all such embodiments and equivalent variations. In addition, the contents of all references cited herein are hereby incorporated by reference.

Claims (7)

1. Application of Drosophila DmAtg5 gene in preparation of anti-Salmonella enteritidis drugs.
2. The use as claimed in claim 1, wherein the anti-salmonella enteritidis drug comprises a substance that enhances the expression of the DmAtg5 gene.
3. The use of claim 1, wherein the primer sequence for detecting Salmonella enteritidis is as follows
Dmrp49-F：GACAGTATCTGATGCCCAACA；
Dmrp49-R：CTTCTTGGAGGAGACGCCGT；
InvC-F：TCAAGAATAGAGCGAATTTCATCC；
InvC-R：TGCTTTTTATCGATTCCATGACCC。
4. Application of Drosophila DmAtg5 gene in screening of drugs for inhibiting Salmonella enteritidis activity.
5. An siRNA for inhibiting the expression of DmaAtg 5 gene of drosophila, wherein the nucleotide sequence of the siRNA is as follows:
F：GCAUUAAGCCGGAGCCUUUTT；
R：AAAGGCUCCGGCUUAAUGCTT。
6. siRNA according to claim 5, wherein said siRNA is useful in screening for agents that inhibit Salmonella enteritidis activity.
7. The use of the siRNA of claim 5 in screening for agents that inhibit Salmonella enteritidis activity.
CN202010473672.XA 2020-05-29 2020-05-29 Application of Dmatg5 gene in preparation of anti-salmonella enteritidis medicine Active CN111701019B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010473672.XA CN111701019B (en) 2020-05-29 2020-05-29 Application of Dmatg5 gene in preparation of anti-salmonella enteritidis medicine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010473672.XA CN111701019B (en) 2020-05-29 2020-05-29 Application of Dmatg5 gene in preparation of anti-salmonella enteritidis medicine

Publications (2)

Publication Number Publication Date
CN111701019A CN111701019A (en) 2020-09-25
CN111701019B true CN111701019B (en) 2021-10-26

Family

ID=72538282

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010473672.XA Active CN111701019B (en) 2020-05-29 2020-05-29 Application of Dmatg5 gene in preparation of anti-salmonella enteritidis medicine

Country Status (1)

Country Link
CN (1) CN111701019B (en)

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Autophagy Controls Salmonella Infection in Response to Damage to the Salmonella-containing Vacuole;Cheryl L.Birmingham,et al;《THE JOURNAL OF BIOLOGICAL CHEMISTRY》;20060421;第281卷(第16期);第11374-11383页 *
Salmonella Interacts With Autophagy to Offense or Defense;Wu,et al;《Frontiers in Microbiology》;20200422;第11卷;第1-13页 *
乳酸杆菌对LPS诱导小鼠肠道过度自噬的保护作用及机制研究;刘丽;《中国优秀硕士学位论文全文数据库 医药卫生科技辑》;20170515(第5期);第E059-63页 *
肠上皮特异性敲除自噬基因Atg5/Atg7小鼠肠道微生物宏基因组测序分析;赵文静;《中国优秀硕士学位论文全文数据库 医药卫生科技辑》;20160415(第4期);第D050-11页 *
赵文静.肠上皮特异性敲除自噬基因Atg5/Atg7小鼠肠道微生物宏基因组测序分析.《中国优秀硕士学位论文全文数据库 医药卫生科技辑》.2016,(第4期),第D050-11页. *

Also Published As

Publication number Publication date
CN111701019A (en) 2020-09-25

Similar Documents

Publication Publication Date Title
Pérez-Ramos et al. β-Glucan-producing Pediococcus parvulus 2.6: test of probiotic and immunomodulatory properties in zebrafish models
US9903002B2 (en) Non-coding RNA of Salmonella and identification and use thereof
Bui et al. Prolonged growth of a clinical Staphylococcus aureus strain selects for a stable small-colony-variant cell type
Nasser et al. Specification of bacteriophage isolated against clinical methicillin-resistant staphylococcus aureus
Trimpert et al. Elizabethkingia miricola infection in multiple anuran species
Kim et al. Nocardia seriolae infection in the cultured eel Anguilla japonica in Korea
CN110484513A (en) Bacteriophage pAhMJG and its application in the fish disease that treatment Aeromonas hydrophila causes
Amalina et al. Recent update on the prevalence of Vibrio species among cultured grouper in Peninsular Malaysia
CN113444785A (en) SSc-miR-122-5p related to piglet C-type clostridium perfringens infectious diarrhea and application thereof
Tashakkori et al. Genotypic and phenotypic diversity of Prototheca spp. recovered from bovine mastitis in terms of antimicrobial resistance and biofilm formation ability
Yespembetov et al. Phenotypic and genotypic characteristics of Brucella isolates from the Republic of Kazakhstan
Paździor et al. Genotypic diversity among Shewanella spp. collected from freshwater fish
CN111701019B (en) Application of Dmatg5 gene in preparation of anti-salmonella enteritidis medicine
KR20200123246A (en) Mycoplasma detection method using mitochondrial DNA as an internal reference sample
CN107653308B (en) One group is combined and kit for distinguishing active tuberculosis patient with the primer pair of non-tuberculous pneumonia patient
Costa et al. Swine dysentery disease mechanism: Brachyspira hampsonii impairs the colonic immune and epithelial repair responses to induce lesions
CN103667271B (en) The primer of detection by quantitative Candida albicans bacterium and probe and application thereof
CN101586157A (en) Diagnostic kit for Streptococcus iniae molecule and detection method
EP3958690A1 (en) Probiotics to inhibit enteric pathogens
CN113444726B (en) A lncRNA ALDB-898 associated with piglet bacterial diarrhea and its application
CN115029323B (en) Drug-resistant staphylococcus aureus phage SP160 and application thereof in preparation of bacteriostat
Voronina et al. Regularities of the ubiquitous polyhostal microorganisms selection by the example of three taxa
WO2015085903A1 (en) Non-coded rna of in-vivo infected microorganisms, parasitic microorganisms, symbiotic microorganisms and identification and application thereof
CN110214181A (en) Novel vibrio parahaemolyticus phage VIB-PAP-4 and its purposes for inhibiting vibrio parahaemolytious bacterial multiplication
JP6435462B2 (en) Microbial culture method

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant